Background: Accumulation in the brain of small aggregates of amyloid ␤-protein 42 (A␤42) is the major pathogenic event of Alzheimer disease (AD). In familial early-onset AD this event is likely the result of A␤42 overproduction; in the most common sporadic late-onset form of the disease the mechanisms of A␤42 accumulation are unknown. Methods: To address this issue the authors analyzed plasma levels of A␤42 in 88 elderly patients with amnestic mild cognitive impairment (MCI), chosen as paradigm of preclinical sporadic AD. Results: The authors found a significant increase of A␤42 plasma levels in women with MCI, in comparison to the affected men and 72 cognitively normal age-matched subjects. The levels were independent of variables in education, apolipoprotein E genotype, cholesterol, and creatinine plasma concentrations, as well as hemoglobin content. Conclusions: The elevation of A␤42 plasma levels in women with MCI may represent a biologic explanation for the sex-dependent increased incidence of late-onset AD in women identified by epidemiologic studies.
The accumulation in the brain of aggregates of amyloid ␤-protein species ending at residue 42 (A␤42) is the major pathogenic event of Alzheimer disease (AD). 1 Supporting this, most of the gene mutations associated with the early-onset familial form of AD (FAD) are associated with an increase in cellular production of A␤42. 2 In sporadic late-onset AD, which accounts for 99% of cases, the pathogenic role of A␤42 is debated. Indeed, solid clues in favor of A␤42 overproduction are lacking, and various heterogeneous factors are suspected to produce its cerebral accumulation, through increased aggregation and defective clearance. 3 In sporadic AD patients with dementia, plasma levels of A␤42 are similar to those of normal controls. 4, 5 However, aged subjects who developed an AD-type dementia within 4 years have higher amounts of plasma A␤42, suggesting that elevated A␤42 is an early initiator of the pathologic process. 6 Mild cognitive impairment (MCI) is a condition characterized by deficit of a single cognitive function not associated with other signs of cognitive deterioration or impairment of daily living activities. 7 A great deal of evidence indicates that the MCI characterized by isolated memory loss (also named amnestic MCI) is incipient AD. For example, MCI patients develop AD-type dementia at the rate of 12% per year, greatly exceeding the 1% to 2% incidence of normal controls, resulting in an 80% conversion from MCI to AD within 6 years. 8, 9 Further, all autopsied amnestic MCI cases show cerebral lesions consistent with the pathologic diagnosis of AD. 10 On these grounds, amnestic MCI is the ideal condition to study the relationship between plasma levels of A␤ species and late-onset sporadic AD.
We measured the plasma concentrations of A␤42 and A␤40 in 88 MCI patients compared with a group of 72 age-matched normal controls, paying attention to variables [11] [12] [13] known to influence A␤ production, aggregation, and excretion.
Methods. The MCI cases were selected among outpatients at their first evaluation, having at least 8 years of education, of three Alzheimer's centers, belonging to a research group on MCI granted by the Minister of Health, Italy. In all patients thyroid and metabolic function tests, as well as brain CT scan, were normal. Neuropsychological tests, with cutoff scores adjusted for age and education of the Italian population, 14 were used to evaluate multiple cognitive functions, including the immediate and delayed recall of a short story and word list memory test, two tests specific for episodic memory 7, 15, 16 (table 1) .
Thus, subjects with a score of both memory tests 1.5 SD below the mean of the proper age, a Clinical Dementia Rating (CDR) score of 0.5, and a Global Deterioration Scale (GDS) score below 14, were diagnosed with amnestic MCI. 8 The mean educational level (years of school) of MCI cases was 9.5 Ϯ 2.6, and it was slightly higher in men (10.1 Ϯ 1.7) compared to women (8.9 Ϯ 2.4), but without a statistical difference (table 2). Control cases were selected age-matched neurologically normal people with normal scores at the memory tests battery, as well as 0 and more than 28/30 at CDR and Mini-Mental State Examination (MMSE). Controls were recruited from patients undergoing surgical operations or with arthritis, and submitted to routine blood tests. Following informed consent, and approval of the ethical committee of the Medical School of Genoa University, peripheral blood samplings of 88 patients with MCI and 72 age-matched controls were obtained after 12 hours fasting (see table 2 ). The mean ages of the subgroups of MCI and control cases separated by sex did not differ significantly from each other (see table 2 ).
In the MCI cases memory disturbances appeared 4 to 6 months before the examination. None of the women from either MCI or control groups were using hormone replacement therapy (HRT). Cholesterol and creatinine plasma levels were measured in the MCI and control groups. Since part of circulating A␤ is bound to red blood cells, 17 we compared hemoglobin and total plasma proteins content in MCI and control groups. The apoE genotype was assessed in the MCI cases with standard procedures. 18 In 54 out patients with probable AD, diagnosed according to National Institute of Neurological and Communicative Disorders and Stroke criteria, 19 the apoE genotype was evaluated as an internal control.
Blood samples, collected into polypropylene tubes containing EDTA, were centrifuged at 1,000 g for 10 minutes at 4°C to obtain plasma fraction and stored at Ϫ80°C. The plasma levels of A␤40 and A␤42 were measured by sandwich ELISA method following the manufacturer's instructions (IBL, Gumna, Japan). The measurement range of this assay is given between 7 and 500 pg/mL of proteins, for both A␤ species. ELISA analysis of all samples was performed in two different experiments to test the reliability of A␤ species measurement. Although the A␤ 42 plasma concentrations of two women with MCI outlined by twofold the mean level, we ascertained that the inclusion in the statistical analysis of these two values did not influence the statistical analysis. The specimens storage conditions used before and during the assay were standardized in order to avoid any experimental artifact.
Plasma A␤40 and A␤42, cholesterol, and creatinine levels were compared among the groups and subgroups of cases using the Student unpaired t and Bonferroni test as post-test. Multiple regression analysis with stepwise procedure was performed to find which variable, from age, apoE, A␤ 40, RBC count, hemoglobin, creatinine, total cholesterol, total protein level, and education level (as years of school), best predicts the value of A␤42 (dependent variable). Data are presented as mean Ϯ standard error.
Results. In the MCI group A␤42 plasma levels were slightly higher than in control subjects, but did not reach significance (MCI: 20.05 Ϯ 1.60 pg/mL; controls: 15.60 Ϯ 1.57 pg/mL) (figure 1).
However, when grouped for sex, women with MCI had concentrations of A␤42 significantly higher than healthy women (MCI: 24.97 Ϯ 2.70 pg/mL; controls: 16.57 Ϯ 2.28 pg/mL; p Ͻ 0.05) ( figure 2A) , while no differences between affected and healthy men were found (MCI: 15.12 Ϯ 1.40 pg/mL; controls: 14.63 Ϯ 2.19 pg/mL) ( figure 2B ). Also, differences in A␤42 plasma levels concentration were found within the MCI group with women showing an average A␤42 concentration 1.5 fold higher than that of men (24.97 pg/mL vs 15.12 pg/mL; p Ͻ 0.002). No significant sex-related differences were found for A␤40 within the MCI group (men 286.2 Ϯ 40.8 pg/mL; women 343.2 Ϯ 57.5 pg/mL) ( figure 3A) , as well as between MCI and control cases (MCI 314.7 Ϯ 35.2 pg/mL; controls 317.7 Ϯ 36.3 pg/mL) ( figure 3B) .
In MCI cases the apoE allele ⑀4 frequency was 0.16, and it was slightly higher in women (0.18) in comparison to men (0.15). The apoE allele ⑀4 frequency of a group of 54 outpatients with probable AD followed by the same Alzheimer centers was 0.25. In the MCI group the presence of apoE allele ⑀4 did not correlate with the levels of A␤42, either if all the cases were considered or within the subgroups of female and male patients ( figure 4 ). All the subjects with MCI showed normal levels of creatinine (see table 2), which was shown to positively correlate with A␤ plasma levels. 13 Moreover, we did not find significant difference of cholesterol plasma levels among all groups of cases examined (see table 2 ). The levels of hemoglobin were similar in MCI and controls (see table 2 ).
Multiple regression analysis, performed in subjects with MCI together with controls to reveal which variable significantly contributes to the variability of A␤42, showed that no variable significantly predicts the value variance. Similarly, the analysis of MCI group alone (including apoE) and the male and female subgroups showed that no variable has significant weight in the variance of A␤42.
Stepwise analysis showed no significant figure. Therefore only sex provides additional information.
Plasma A␤ levels were measured at 12 months since the first evaluation in 19 out of 88 MCI cases. We observed that A␤42 concentrations dropped only in women (29.03 pg/mL vs 12.54 pg/mL, n ϭ 9), and that the decrease was larger (43.57 pg/mL vs 10.41 pg/mL) in the three cases evolved in probable AD.
Discussion. This study shows that women with MCI have plasma levels of A␤42 significantly higher than cognitively normal age-matched subjects or men with MCI.
Our findings have several implications. First, because epidemiologic and neuropathologic data indicate that the amnestic MCI is a very early stage of AD, 8, 9 the increase of A␤42 plasma concentrations in women with MCI links the overproduction of this peptide with the gender dependent occurrence of spo- radic late-onset AD. This interpretation is consistent with previous data showing that an elevation in plasma of A␤42 is clearly detectable only when its cellular overproduction occurs, caused by gene mutations associated with the early-onset FAD. 2 In FAD cases plasma levels of A␤42 decrease during the course of the disease, mainly because of the progressive degeneration of its major source, the neuronal cells. 20 Our results suggest that A␤42 overproduction also occurs in women with sporadic late-onset AD and that elevated plasma concentrations of A␤42 is detectable only in a preclinical stage, before the onset of dementia. Later on, when cognitive dysfunction causes alteration of daily living activities, compatible with the diagnosis of probable AD, A␤ levels are similar to normal controls, as suggested by values detected in our cases evaluated at 12 months since the first observation, and indicated by studies on definite AD. 4, 5 The selective increase of A␤42 plasma levels in women with MCI is directly correlated to the sex-dependent difference in the incidence of late-onset sporadic AD. Epidemiologic studies show that the incidence rate of AD is 0.8/100 a year in men and 1.4/100 a year in women after 80 years of age. 21 The role of postmenopausal drop of estrogens as a risk factor of AD is debated. 22, 23 Similarly, contrasting clues on the role of HRT have emerged. 24 Observational studies have suggested that HRT would decrease the risk of dementia. 25, 26 Instead, recent randomized trials showed an increased risk for dementia of combined estrogen and progestin treatment. 27, 28 In these studies hormone therapy was begun at 65 years of age, later than is usually prescribed as postmenopausal replacement. The findings of the present study shed light on the contrasting results: estrogens may influence the long preclinical phase of A␤42 accumulation in brain tissue, whereas they do not improve the already triggered neuronal degeneration. In agreement with this interpretation, a correlation recently was found between early onset of menopause and risk of AD in women with Down syndrome. 29 This hypothesis is also supported by biologic clues, because estrogens reduce A␤ production in vitro, as well as A␤ accumulation in mutant APP transgenic mice. [30] [31] [32] The pathogenic role of A␤ in sporadic AD is a debated issue. Our findings showed a specific correlation between plasma levels of A␤42 and the preclinical stage of the disease in women. This result is limited by the relatively small number of cases that we analyzed, and it needs further confirmation. Then, the significance of the relationship can be elucidated correlating A␤42 plasma levels with the clinical evolution of MCI patients.
